Comparative treatment persistence with bone-targeting agents among Asian patients with bone metastases from solid tumors: a multinational retrospective cohort study

According to the results of a population-based cohort study of 5,127 patients in Taiwan, Hong Kong, and Korea with breast, lung, or prostate cancer and bone metastases who received bone-targeting agents, denosumab had a lower risk of interruption in Taiwan (adjusted HR 0.44; 95% CI 0.40-0.48) and Hong Kong (adjusted HR 0.36; 95% CI 0.28-0.45), compared with zoledronic acid. Pamidronate was more likely to be interrupted than zoledronic acid in Taiwan (adjusted HR 1.31; 95% CI 1.11-1.54) and Korea (adjusted HR 2.06; 95% CI 1.83-2.32), but not in Hong Kong (adjusted HR 1.13; 95% CI 0.71-1.78).